Device Trial Radar · NCT07832929
Gelified Radiopaque Ethanol (Absolute Gel) in Cervical Disc Herniation: an Observational Study in Routine Clinical Practice (GENESIS)
Last checked: Nov 20, 2026Latest source record: Sep 22, 2026 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
45
Planned (sponsor's estimate)
Start
Mar 10, 2025
Primary completion
Nov 23, 2026
Study completion Nov 23, 2030
Sponsor
- Lead sponsor
- Aurel MengriAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- First posted
- Sep 22, 2026
Design
- Study type
- Observational
- FDA-regulated device
- No
- Who can join
- All sexes, from 18 years, up to 75 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
GENESIS is a single-centre, observational, non-interventional, no-profit, investigator-initiated study conducted at Ospedale di Vimercate, ASST Brianza (Italy). The study describes the clinical and functional course of adult patients with cervical disc herniation and chronic discogenic neck pain who receive intradiscal radiopaque gelified ethanol (Absolute Gel), a CE-marked Class III medical device, as part of routine clinical practice and within its approved indications. The study does not assign, introduce or modify any treatment, procedure, medication or follow-up schedule. The decision to treat is taken exclusively by the treating physician according to standard clinical practice. The study only collects clinical and radiological data generated during routine care, both retrospectively (patients already treated) and prospectively (patients treated independently of study participation). Approximately 45 participants are planned. The main descriptive measure is the proportion of participants achieving a reduction of at least 30% in neck pain intensity (Visual Analogue Scale, VAS) at 1 month compared with baseline. Participants are followed up to 48 months after treatment. All analyses are descriptive. The study is not designed to demonstrate efficacy, to support causal inference, or to perform comparisons with other treatments.
Conditions
- Cervical Disc Herniation
- Intervertebral Disc Displacement
- Neck Pain
- Chronic Pain
- Radiculopathy
Interventions
Absolute Gel (radiopaque gelified ethanol)Device
CE-marked Class III medical device used within its approved indications as part of standard clinical care. Intradiscal injection of radiopaque gelified ethanol at the cervical level, performed under fluoroscopic guidance through an antero-lateral approach with local anaesthesia, typically 0.3 to 0.4 mL per disc. The study does not assign, impose or modify the treatment, the technique or the peri-procedural management; it records the procedure as performed in routine practice.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Proportion of participants with a reduction of at least 30% in neck pain intensity (VAS) at 1 monthTime frame: Baseline and 1 month (+/-14 days) after treatment
- Change from baseline in neck pain intensity (VAS) at 1 monthTime frame: Baseline and 1 month (+/-14 days) after treatment
Locations
1 site in 1 country. Site status is shown where the registry gives one.
Ospedale di Vimercate - ASST Brianza
Vimercate, Monza E Brianza, Italy · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.